Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06200194

Early Intervention for Premyopic Children

The purpose of this research project is to add evidence of pharmacological (0.01% atropine) and optical (Defocus Integrated Multiple Segments spectacle lenses) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention strategy for myopia control in premyopic children.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

5 year–6 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

National Yang Ming Chiao Tung University Hospital

Yilan, Taiwan, 26058

About this study

With more popularity of screen-based digital devices in the post-pandemic era, childhood myopia prevention and control has encountered a tough challenge on a global scale. Though the protective effect of spending more time outdoors has been well proven, the optimal practice for preventing or delaying the early onset of childhood myopia still needs further investigations, particularly in pre-myopic children around the school entrance age. It has been reported that there is a double-digit increase in myopia prevalence before and after elementary school entry, and young children with early-onset myopia are at great risk of rapid progression to high myopia later in life. Most recently, nightly use of 0.05% atropine eye drops is effective in reducing the incidence of childhood myopia. However, photophobia is a common adverse effect of higher concentration atropine, which may hinder children from daytime outdoor activities. Besides, little is known about the optical approach for myopia prevention in the existing literature. These unmet demands in clinical practice motivate us to propose a randomized controlled trial on myopia prevention with optical (Defocus Incorporated Multiple Segments [DIMS] spectacle lenses) or pharmacological (0.01% atropine eye drops) modalities among pre-myopic preschoolers aged 5-6 years. To explore the adaptability and feasibility of DIMS spectacle lenses for pre-myopic children with normal visual acuity, we have conducted a pilot study and revealed that all 24 subjects can tolerate daily full-time wearing of DIMS spectacle lenses without significant visual complaints. In this proposal, we plan to recruit a total of 234 eligible participants who have been identified as pre-myopic and asymptomatic in a population-based eye care program in Yilan County. Eligible subjects will be randomly assigned to the DIMS spectacles (n=78), 0.01% atropine (n=78), and usual care (n=78) groups. Less environmental pressure is hypothesized in preschool compared with elementary school. Hence, pre-myopic children will be asked to wear DIMS spectacle lenses in a stepwise pattern: at-home wearing in the preschool stage and full-time in the elementary school stage. Cycloplegic spherical equivalent (SE) refraction and axial length will be measured every 3 months over the 18-month follow-up period. The primary outcome is the changes in mean cycloplegic SE over the study period in each group. The secondary outcomes include the cumulative percentage of incident myopia, the cumulative percentage of a fast myopic shift of SE, and the changes in mean axial length over the study period in each group. This proposed project may offer insight into the intervention strategy for myopia prevention and evoke the possibility of a reinvented eye care policy that may focus on early identification and intervention for pre-myopic preschoolers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age at enrollment: 5-6 years old (the senior grade of kindergarten)
  • Cycloplegic SE of the eye with less SE (less positive or more negative refractive error): < +1.00 D and > -0.50 D
  • Astigmatism: 1.0 D or less in both eyes
  • Anisometropia: 1.50 D or less
  • Monocular uncorrected visual acuity: 6/7.5 or better in both eyes
  • Either of the parents with moderate myopia
  • Acceptance of random group allocation
  • Submission of complete informed consent.

Exclusion criteria

  • Strabismus or any ocular motility disorder
  • Any ophthalmic and systemic disorders that might affect visual functions or refractive development
  • Previous treatment of atropine or other myopia control intervention

Treatment and study plan

MiyoSmart Spectacles

Device

No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.

Other names: MiyoSmart (Hoya, Tokyo, Japan)

0.01% atropine

Drug

daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.

Other names: "AIM" Atropine Eye Drops 0.01% (AIMedicine, Taipei, Taiwan)

Primary outcomes

  1. Myopic shift of spherical equivalent refraction

    Time frame: 18 months

    The change of mean cycloplegic spherical equivalent refraction over 1.5 years

Secondary outcomes

  1. Axial length elongation

    Time frame: 18 months

    The change of mean axial length over 1.5 years

  2. Incidence of myopia

    Time frame: 18 months

    the cumulative percentage of incident myopia

  3. Fast myopic shift of spherical equivalent refraction

    Time frame: 18 months

    the cumulative percentage of fast myopic shift of spherical equivalent refraction

Sponsors and collaborators

Lead sponsor

National Yang Ming Chiao Tung University Hospital

Other

Collaborators

  • National Science and Technology Council, Taiwan

Registry information

Official study title

Early Intervention for Premyopic Children: A Comparison Study of Defocus Integrated Multiple Segments Spectacle Lenses, 0.01% Atropine and Usual Care for Myopia Prevention

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 10, 2024
Registry last updated
Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.